Usage of different lots of RLDs in multistage adaptive studies [Regulatives / Guidelines]

posted by ElMaestro  – Denmark, 2018-09-20 12:19 (960 d 08:08 ago) – Posting: # 19294
Views: 1,467

Hi manusyriac,

» Can we use different lots of RLDS in multistage studies as the study design requires more than 2 years of shelf-life for RLDs. If it is possible please help me to find any relevant regulatory guidance for the same.

Without being absolutely sure I think this would be ok with most EU authorities for the reasons you state. Less convinced about how HC or FDA or PMDA would see it.
Note that in your case batch and stage will have the same meaning for the product(s) in question.

Pass or fail!

Complete thread:

 Admin contact
21,445 posts in 4,482 threads, 1,511 registered users;
online 19 (1 registered, 18 guests [including 6 identified bots]).
Forum time: Friday 20:28 CEST (Europe/Vienna)

The plural of anecdote is not data.    Roger Brinner

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz